SCM
SGMT icon

Silverarc Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Silverarc Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
+2,927,698
New +$19.9M 2.35% 14
2025
Q3 		– Sell
-37,539
Closed -$286K – 93
2025
Q2 		$286K Buy
+37,539
New +$158K 0.05% 61
2023
Q4 		– Sell
-100,000
Closed -$880K – 84
2023
Q3 		$880K Buy
+100,000
New +$1.33M 0.27% 62

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Silverarc Capital Management's SGMT Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 2,927,698 shares worth $22.6M. The stake represents 2.35% of the portfolio and ranks #14 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in SGMT as recently as Q2 2025.

Silverarc Capital Management first reported a position in SGMT in Q3 2023 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Silverarc Capital Management held 2,927,698 shares of Sagimet Biosciences worth $22.6M as of Q2 2026.
  • Sagimet Biosciences was a new Silverarc Capital Management position in Q2 2026.
  • Sagimet Biosciences made up 2.35% of Silverarc Capital Management's portfolio in Q2 2026, its #14 holding.
  • Silverarc Capital Management first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 3 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.